Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study

Journal:
The Lancet
Published:
Affiliations:
35
Authors:
29
Institutions Authors Share
Merck & Co, United States of America (USA)
3.000000
0.10
IRCCS European Institute of Oncology (IEO), Italy
2.000000
0.07
Roswell Park Cancer Institute (RPCI), United States of America (USA)
1.000000
0.03
IRCCS Mario Negri Institute, Italy
1.000000
0.03
CHU de Québec, UL, Canada
1.000000
0.03
Narodowy Instytut Onkologii, Poland
1.000000
0.03
Rambam Health Care Campus (RambamHCC), IIT, Israel
1.000000
0.03
Saitama Medical University International Medical Center, Japan
1.000000
0.03
Başkent University, Turkey
1.000000
0.03
Centro Oncológico Internacional (COI), Mexico
1.000000
0.03
University Hospitals Sussex NHS Foundation Trust, United Kingdom (UK)
1.000000
0.03
Leiden University Medical Center (LUMC), Netherlands
1.000000
0.03
National Cancer Institute (INCA), Brazil
1.000000
0.03
Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Colombia
1.000000
0.03
Turku University Hospital (TYKS), UTU, Finland
1.000000
0.03
Sant'Orsola Malpighi Hospital, Italy
1.000000
0.03
Obstetrics and Gynecology Hospital, Fudan University, China
1.000000
0.03
Florida Cancer Specialists and Research Institute (FCS), United States of America (USA)
1.000000
0.03
Texas Oncology, United States of America (USA)
1.000000
0.03
Fudan University Shanghai Cancer Center (FUSCC), China
1.000000
0.03
Bradford Hill, Chile
0.500000
0.02
University Finis Terrae (UFT), Chile
0.500000
0.02
Epworth HealthCare, Australia
0.500000
0.02
Peter MacCallum Cancer Centre (Peter Mac), Australia
0.500000
0.02
Seoul National University (SNU), South Korea
0.500000
0.02
APGOT Korea, South Korea
0.500000
0.02
Charité - University Medicine Berlin, Germany
0.500000
0.02
North-Eastern-German Society of Gynaecologic Oncology (NOGGO e.V.), Germany
0.500000
0.02
Centre Eugène Marquis (CEM), France
0.500000
0.02
ARCAGY-GINECO, France
0.500000
0.02
AZ Groeninge, Belgium
0.250000
0.01
Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Belgium
0.250000
0.01
Anglia Ruskin University, United Kingdom (UK)
0.250000
0.01
University of Plymouth, United Kingdom (UK)
0.250000
0.01